Previous 10 | Next 10 |
- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy - - Pre-registration available for live event, to be held Tuesday, June 27, 2023 at 2:00 p.m. ET - BOSTO...
- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, wil...
2023-05-09 08:52:05 ET Sensei Biotherapeutics press release ( NASDAQ: SNSE ): Q1 GAAP EPS of -$0.33 beats by $0.02 . Cash, cash equivalents and marketable securities were $95.5 million as of March 31, 2023, as compared to $107.1 million as of December 31, 2022. Sensei ...
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 - - Signing of key collaborations underscore potential of conditional activation and VISTA mechanism - - AA...
2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...
2023-04-21 09:15:38 ET Satixfy Communications ( SATX ) -17% . Aditxt ( ADTX ) -11% . Everbridge ( EVBG ) -10% . Augmedix ( AUGX ) -7% . Sensei Biotherapeutics ( SNSE ) -7% . Blackboxstocks ( BLBX ) -6% . Big Lots ( ...
2023-04-20 08:18:28 ET Sensei Biotherapeutics ( NASDAQ: SNSE ) received US FDA approval for its Investigational New Drug ( IND ) application for SNS-101, an antibody for solid tumors. The company will now proceed with a phase 1 trial of SNS-101 as both monotherapy and ...
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investi...
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a condit...
News, Short Squeeze, Breakout and More Instantly...
Sensei Biotherapeutics Inc. Company Name:
SNSE Stock Symbol:
NASDAQ Market:
Sensei Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEW...